You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,251,934


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,251,934
Title:Syndecan-2 compositions and methods of use
Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
Inventor(s): Elliman; Stephen Joseph (Galway, IE)
Assignee: Orbsen Therapeutics Limited (IE)
Application Number:14/785,001
Patent Claims:1. A method of inhibiting a T cell proliferation response, comprising contacting a cell to a composition comprising Syndecan-2 (SDC2) or a fragment of SDC2 and measuring a reduction in the T cell proliferation response.

2. The method according to claim 1, wherein the SDC2 or the fragment of SDC2 is soluble.

3. The method according to claim 1, wherein the SDC2 is human SDC2.

4. The method according to claim 1, wherein the SDC2 is obtained from a cell culture supernatant.

5. The method according to claim 1, wherein the method comprises contacting the cell to a composition comprising Syndecan-2 (SDC2) or a fragment of SDC2 and further comprising cells or tissue.

6. The method according to claim 1, wherein the method further comprises contacting the cell to an anti-inflammatory agent selected from the group consisting of an anti-TNF.alpha. antibody, infliximab, adalimumab, certolizumab, golimumab, etanercept, an anti-CD3 antibody, muromonab-CD3, otelixizumab, teplizumab, visilizumab, and combinations thereof.

7. The method according to claim 1, wherein the method comprises contacting the cell to a SDC2 polypeptide comprising at least 30 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

8. The method according to claim 7, wherein the contacting the cell to a SDC2 polypeptide comprising at least 30 consecutive residues of the amino acid sequence of SEQ ID NO: 3 comprises contacting a cell to a polypeptide having at least residues 1 to 18 of the amino acid sequence of SEQ ID NO: 3.

9. The method according to claim 1, wherein the method comprises contacting the cell to a SDC2 polypeptide having a sequence with at least 90% identity to the amino acid sequence of SEQ ID NO: 3 over at least 30 consecutive residues.

10. The method according to claim 1, wherein the method comprises contacting the cell to a SDC2 polypeptide having at least 61 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

11. The method according to claim 1, wherein the method comprises contacting the cell to a SDC2 polypeptide having at least 79 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

12. The method according to claim 1, wherein the method comprises contacting the cell to a SDC2 polypeptide having at least 87 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

13. The method according to claim 1, wherein the method comprises contacting the cell to a SDC2 polypeptide having 201 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

14. The method according to claim 1, wherein the cell is related to a patient that has at least one symptom of an inflammatory disease.

15. The method according to claim 1, wherein said SDC2 reduces response of the cell to at least one of Tumor Necrosis Factor-.alpha. (TNF.alpha.), Interleukin-6 (IL6), Interleukin-8 (IL8), and Interleukin-1.beta. (IL1.beta.).

16. The method of claim 1, wherein said SDC2 inhibits a response to a pro-inflammatory cytokine in the cell.

17. A method of inhibiting a NFkB activation in a cell comprising contacting a cell to a composition comprising Syndecan-2 (SDC2) or a fragment of SDC2 and measuring a reduction in the NFkB activation, wherein said SDC2 reduces NFkB activation in the cell.

18. The method of claim 17, wherein the SDC2 or the fragment of SDC2 is soluble.

19. The method of claim 17, wherein the SDC2 is human SDC2.

20. The method of claim 17, wherein the method comprises contacting the cell to a SDC2 polypeptide comprising at least 30 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

Details for Patent 10,251,934

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2033-04-16
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2033-04-16
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2033-04-16
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2033-04-16
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2033-04-16
Immunex Corporation ENBREL MINI etanercept Injection 103795 09/14/2017 ⤷  Try a Trial 2033-04-16
Immunex Corporation ENBREL etanercept Injection 103795 ⤷  Try a Trial 2033-04-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.